1
|
Lopez Campos F, Lorente D, Llacer C, érez P, Gómez-Iturriaga A, Henriquez-López I, Peleteiro P, Ramirez-Backhaus M, Navarro-Castellón J, Lozano R, Romero N, Gajate P, Ana C, Gómez J, Álvarez S, Molina-Cerrillo J, Pelari L, Hernández-Corrales A, Morillo V, García R, Ferrer-Albiach C, Castro E, Olmos D. PD-0908 PSA Progression and survival in mCRPC patients treated with abiraterone or enzalutamide. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07187-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
2
|
Lopez Campos F, Lorente D, Llacer-Pérez C, Henríquez I, Peleteiro P, Gómez-Iturriaga A, Ramírez-Backhaus M, Álvarez S, Alonso-Gordoa T, Molina-Cerrillo J, Vallejo C, Hervás A, Navarro-Castellón J, Gómez J, Morillo V, Lozano R, Romero-Laorden N, García R, Hernández-Corrales A, Pelari L, Ferrer-Albiach C, Sancho S, Castro E, Olmos D. PD-0913 Local treatment to the primary tumor and PSA changes as prognostic factors in mCRPC. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)07192-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
López-Campos F, Lorente D, Llacer Perez C, Ramirez-Backhaus M, Peleteiro P, Gomez-Iturriaga A, Henriquez-López I, Lozano R, Romero N, Alonso-Gordoa T, Molina-Cerrillo J, Navarro-Castellón J, Castaño A, Pelari L, Hernández-Corrales A, Morillo V, García R, Ferrer Albiach C, Castro E, Olmos D. Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.5024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5024 Background: PSA value is widely used for the monitoring of treatment outcome in mCRPC in the clinical real-world setting. Early PSA changes are not considered in the definition of PSAProg due to the potential for spurious “flare” reactions. We aimed to evaluate the significance of an early PSA increase in mCRPC patients (pts) treated with enzalutamide or abiraterone (Enz/Abi). Methods: We retrospectively evaluated Enz/Abi-treated mCRPC pts from 11 hospitals between 2011-2020. Early PSAProg was defined as a 25% increase in PSA from baseline at 4 (PSAProg4) or 8 (PSAProg8) weeks after treatment initiation. PSA progression at 12 weeks (PSAProg12) was confirmed by a second reading. Uni- and multivariable (MV) Cox regression models were conducted to explore the association of PSAProg and overall survival (OS) in chemotherapy naïve patients treated with Abi or Enz. Interaction tests were conducted to explore differences in the impact of PSA progression on OS in Abi or Enz-treated pts. Results: We analyzed 511 chemotherapy-naïve mCRPC pts treated with Abi (N=391; 76.5%) or Enz (N=120; 23.5%). Median follow-up: 30.2 months. OS was longer in Enz-treated pts (38.1 vs 29m; HR 1.4; p=0.027). 59 (15.1%), 70 (17.9%) and 48 (12.3%) of Abi-treated and 9 (7.5%), 11 (9.2%) and 10 (8.3%) of Enz-treated pts experienced PSAProg4, PSAProg8 and PSAProg12, respectively, although differences were not statistically significant. PSAProg was associated with worse OS at all 3 timepoints only in Abi-treated pts. In Enz-treated pts, PSAProg4 had a large impact on OS, not observed in PSAProg8 or PSAProg12. We observed no significant interaction between agent (Enz/Abi) and PSA progression (Table). Conclusions: PSA progression at 4 weeks after Enz/Abi is significantly associated with shorter OS and may help identify pts not benefitting from Abi/Enz before clinical or radiographic progression. PSA pattern progression and its association with OS might differ depending on the drug used (Enz/Abi). Prospective validation studies are needed.[Table: see text]
Collapse
Affiliation(s)
| | - David Lorente
- Medical Oncology Department, Hospital Provincial de Castellón, Castellón De La Plana, Spain
| | | | | | - Paula Peleteiro
- Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
| | | | | | - Rebeca Lozano
- Spanish National Cancer Research Centre, Prostate Cancer Clinical Research Unit, Madrid, Spain
| | - Nuria Romero
- Medical Oncology Department, Hospital Universitario La Princesa,, Madrid, Spain
| | | | | | | | - Ana Castaño
- Radiation Oncology Department Hospital Universitario La Paz, Madrid, Spain
| | - Lira Pelari
- Radiation Oncology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain
| | | | - Virginia Morillo
- Radiation Oncology Department, Hospital Provincial de Castellón, Castellón, Spain
| | - Raquel García
- Hospital Clínico Universitario de Valencia, Valencia, Spain
| | | | - Elena Castro
- Hospitales Virgen de la Victoria y Regional de Málaga, Instituto de Investigación Biomédica de Málaga, Málaga, Spain
| | - David Olmos
- Spanish National Cancer Research Center (CNIO), Madrid, Spain
| |
Collapse
|
4
|
Cadeddu G, Hervás-Morón A, Martín-Martín M, Pelari-Mici L, Ytuza-Charahua de Kirsch K, Hernández-Corrales A, Vallejo-Ocaña C, Sastre-Gallego S, Carrasco-Esteban E, Sancho-García S, López-Campos F. Metformin and statins: a possible role in high-risk prostate cancer. Rep Pract Oncol Radiother 2020; 25:163-167. [PMID: 32021570 DOI: 10.1016/j.rpor.2019.12.027] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2019] [Accepted: 12/30/2019] [Indexed: 01/05/2023] Open
Abstract
Aim and background There is increasing evidence that statins and oral anti-diabetic drugs, such as metformin, can have a favorable role in advanced prostate cancer treatment.Metformin has been shown to inhibit proliferation of tumor cells in vitro and statins inhibit carcinogenesis by suppressing angiogenesis/invasion mechanisms. However, clinical evidence on the protective effect of these drugs is still weak.The purpose of this study is to analyze if these drugs have an impact on Biochemical-Failure-Free-Survival (BFFS) and on Distant-Failure-Free-Survival (DFFS) in localized high-risk prostate cancer. Material and Methods From 2002-2016, 447 patients with histologically confirmed high-risk prostate cancer were retrospectively evaluated. All patients received radiotherapy and androgen deprivation therapy. Biochemical recurrence was determined by the Phoenix criteria and metastatic patients were defined by the presence of radiological metastasis. Survival analysis was performed using the Kaplan-Meier method. Results 175 patients were treated with statins (65.3 % with a dose ≤ 20 mg/day) and 70 with metformin (75.7 % with a dose ≤ 1700 mg/day). Median follow-up was 88 months (1-194) with no differences in BFFS and DFFS between metformin and non-metformin patients (77.4 % versus 80 %, p = 0.91 and 89.4 % versus 88.7 %, p = 0.56, respectively). We did not find a statistical difference in BFFS and DFFS in patients taking higher doses of those drugs. Conclusion Metformin and statins were not associated with BFFS or DFFS improvement in our analysis. However, the small number of patients treated with these drugs limits the reliability of the results and prospective studies are needed.
Collapse
Affiliation(s)
- Giovanna Cadeddu
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Asunción Hervás-Morón
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Margarita Martín-Martín
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Lira Pelari-Mici
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Kathy Ytuza-Charahua de Kirsch
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Antonio Hernández-Corrales
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Carmen Vallejo-Ocaña
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Sara Sastre-Gallego
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Eliseo Carrasco-Esteban
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Sonsoles Sancho-García
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| | - Fernando López-Campos
- Radiation Oncology Department, "Hospital Universitario Ramón y Cajal", Carretera M-607 Colmenar Viejo, km. 9,100, 28034 Madrid, Spain
| |
Collapse
|